Characteristics of study cohort
| Characteristic . | HLA-identical sibling . | Well-matched URD . | Mismatched URD . | Total* . |
|---|---|---|---|---|
| No. of patients | 244 | 229 | 470 | 1117 |
| No. of centers | 101 | 63 | 97 | 183 |
| Patient age, y | ||||
| Median (range) | 14 (< 1-19) | 13 (< 1-19) | 11 (< 1-19) | 12 (< 1-19) |
| < 10 | 73 (30) | 93 (41) | 245 (52) | 497 (44) |
| ≥ 10 | 171 (70) | 136 (59) | 225 (48) | 620 (56) |
| Male | 155 (64) | 135 (59) | 270 (57) | 666 (60) |
| Diagnosis | ||||
| AML | 77 (32) | 58 (25) | 128 (27) | 300 (27) |
| ALL | 112 (46) | 107 (47) | 221 (47) | 546 (49) |
| CML | 39 (16) | 36 (16) | 76 (16) | 172 (15) |
| MDS | 16 (7) | 28 (12) | 45 (10) | 99 (9) |
| Disease status before transplantation | ||||
| Early | 143 (59) | 92 (40) | 161 (34) | 466 (42) |
| Intermediate | 79 (32) | 98 (43) | 242 (51) | 503 (45) |
| Advanced | 22 (9) | 39 (17) | 67 (14) | 148 (13) |
| Graft source | ||||
| Bone marrow | 163 (67) | 168 (73) | 355 (76) | 798 (71) |
| G-CSF mobilized peripheral blood stem cells | 81 (33) | 58 (25) | 48 (10) | 221 (20) |
| Cord blood | 0 | 3 (1) | 67 (14) | 98 (9) |
| Conditioning regimen | ||||
| High dose (ablative) | 237 (97) | 222 (97) | 459 (98) | 1084 (97) |
| Reduced intensity (nonmyeloablative) | 7 (3) | 7 (3) | 11 (2) | 33 (3) |
| Donor/recipient sex match | ||||
| Male/male | 62 (25) | 87 (38) | 143 (30) | 339 (30) |
| Male/female | 53 (22) | 42 (18) | 92 (20) | 207 (19) |
| Female/male | 93 (38) | 48 (21) | 127 (27) | 327 (29) |
| Female/female | 36 (15) | 52 (23) | 108 (23) | 244 (22) |
| Donor-recipient CMV match | ||||
| Donor and recipient CMV (−) | 72 (30) | 100 (44) | 159 (34) | 386 (35) |
| Donor and/or recipient CMV (+) | 161 (66) | 123 (54) | 263 (57) | 649 (58) |
| Unknown | 11 (5) | 6 (3) | 48 (10) | 82 (7) |
| GVHD prophylaxis | ||||
| T-cell depletion | 7 (3) | 73 (32) | 216 (46) | 395 (35) |
| CSA ± MTX ± other | 225 (92) | 120 (52) | 216 (46) | 634 (57) |
| FK506 ± MTX ± other | 12 (5) | 36 (16) | 38 (8) | 88 (8) |
| Year of transplantation | ||||
| 1995-1999 | 164 (67) | 68 (30) | 242 (51) | 577 (52) |
| 2000-2004 | 80 (33) | 161 (70) | 228 (49) | 540 (48) |
| Follow-up of survivors, months, median (range) | 72 (4-163) | 71 (12-153) | 83 (3-149) | 72 (2-162) |
| Characteristic . | HLA-identical sibling . | Well-matched URD . | Mismatched URD . | Total* . |
|---|---|---|---|---|
| No. of patients | 244 | 229 | 470 | 1117 |
| No. of centers | 101 | 63 | 97 | 183 |
| Patient age, y | ||||
| Median (range) | 14 (< 1-19) | 13 (< 1-19) | 11 (< 1-19) | 12 (< 1-19) |
| < 10 | 73 (30) | 93 (41) | 245 (52) | 497 (44) |
| ≥ 10 | 171 (70) | 136 (59) | 225 (48) | 620 (56) |
| Male | 155 (64) | 135 (59) | 270 (57) | 666 (60) |
| Diagnosis | ||||
| AML | 77 (32) | 58 (25) | 128 (27) | 300 (27) |
| ALL | 112 (46) | 107 (47) | 221 (47) | 546 (49) |
| CML | 39 (16) | 36 (16) | 76 (16) | 172 (15) |
| MDS | 16 (7) | 28 (12) | 45 (10) | 99 (9) |
| Disease status before transplantation | ||||
| Early | 143 (59) | 92 (40) | 161 (34) | 466 (42) |
| Intermediate | 79 (32) | 98 (43) | 242 (51) | 503 (45) |
| Advanced | 22 (9) | 39 (17) | 67 (14) | 148 (13) |
| Graft source | ||||
| Bone marrow | 163 (67) | 168 (73) | 355 (76) | 798 (71) |
| G-CSF mobilized peripheral blood stem cells | 81 (33) | 58 (25) | 48 (10) | 221 (20) |
| Cord blood | 0 | 3 (1) | 67 (14) | 98 (9) |
| Conditioning regimen | ||||
| High dose (ablative) | 237 (97) | 222 (97) | 459 (98) | 1084 (97) |
| Reduced intensity (nonmyeloablative) | 7 (3) | 7 (3) | 11 (2) | 33 (3) |
| Donor/recipient sex match | ||||
| Male/male | 62 (25) | 87 (38) | 143 (30) | 339 (30) |
| Male/female | 53 (22) | 42 (18) | 92 (20) | 207 (19) |
| Female/male | 93 (38) | 48 (21) | 127 (27) | 327 (29) |
| Female/female | 36 (15) | 52 (23) | 108 (23) | 244 (22) |
| Donor-recipient CMV match | ||||
| Donor and recipient CMV (−) | 72 (30) | 100 (44) | 159 (34) | 386 (35) |
| Donor and/or recipient CMV (+) | 161 (66) | 123 (54) | 263 (57) | 649 (58) |
| Unknown | 11 (5) | 6 (3) | 48 (10) | 82 (7) |
| GVHD prophylaxis | ||||
| T-cell depletion | 7 (3) | 73 (32) | 216 (46) | 395 (35) |
| CSA ± MTX ± other | 225 (92) | 120 (52) | 216 (46) | 634 (57) |
| FK506 ± MTX ± other | 12 (5) | 36 (16) | 38 (8) | 88 (8) |
| Year of transplantation | ||||
| 1995-1999 | 164 (67) | 68 (30) | 242 (51) | 577 (52) |
| 2000-2004 | 80 (33) | 161 (70) | 228 (49) | 540 (48) |
| Follow-up of survivors, months, median (range) | 72 (4-163) | 71 (12-153) | 83 (3-149) | 72 (2-162) |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CMV, cytomegalovirus; CSA, cyclosporine A; and MTX, methotrexate.
Other related (n = 86) and patients missing HLA data (n = 88) are not included in the donor columns. These groups are included in the Total column.